(403) 770-2469 info@marvelbiotechnology.com
Marvel Biosciences
  • About Us
  • Technology
    • MB-204
    • Non-Hallucinogenic Neuroplasticity Program
  • News
  • Investors
  • Contact Us
Select Page

Marvel Biosciences to File for Orphan Drug Designation with the U.S. FDA for MB-204 as a Treatment for Rett Syndrome

Mar 17, 2025 | News

Calgary, Alberta – March 17, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announced plans to file for Orphan Drug Designation (ODD) with the U.S. Food and...
  • Twitter
Copyright 2022 Marvel Biosciences Corp. All rights reserved.